Medicalook
Medicalook

Alglucerase

http://www.medicalook.com
Alglucerase

Alglucerase review





The alglucerase injection, also known by its brand name Ceredase, is a modified version of the β-glucocerebrosidase enzyme, also known as β-D-glucosyl-N-acylsphingosine glucohydrolase, EC 3.2.1.45. Alglucerase and glucocerebrosidase act as catalysts to the glycolipid's hydrolysis (glucocerebroside) inside the lysosomes of the reticuloendothelial system.

This enzyme is utilized as a medication to restore the deficiencies found in patients suffering from Gaucher's disease. This drug decreases complications and relieves symptoms associated with the aforementioned condition.

Alglucerase can be taken via intravenous infusion over the course of one to two hours. Each dose should be administered in a case-to-case basis depending on the patient. Dosage may vary from 2.5 units per kilogram of body weight given three times a week to a maximum of 60 units per kilogram given once a week or once a month. 60 units per kilogram every two weeks is the most common dose used, and it's also the dose where most information on alglucerase's effectiveness is available.

If your condition is particularly severe, the drug may be dosed at a high amount or given to you frequently from the very start. Once a positive response to the drug has been achieved, dosage can be reduced in order to begin maintenance treatment of the patient. Gradual reductions can be done at intervals of three to six months while carefully analyzing the patient's response to the decreasing doses.

Tests conducted with over one thousand patients treated with this medication have yielded a small number of different side effects. Some of these issues are connected with the administration route. For example, the site of venipuncture sometimes produces sterile abscess, swelling, burning, pruritus, and discomfort. The remaining side effects include vomiting, nausea, abdominal discomfort, chills, and slight fever. None of the above side effects are severe enough to require medical intervention.

Conversely, during rare cases of hypersensitivity, the following symptoms have happened during or shortly after infusions: abdominal cramping, chest discomfort, symptoms of respiratory disorder, nausea, urticaria, angioedema, pruritus, and flushing. Hypotension has been known to occur during a few of these instances.

Inform your healthcare specialist immediately of any OTC (over the counter) or prescription drug you may be taking. More to the point, you must not begin or halt any treatment without prior doctor or pharmaceutical approval. You must also tell your physician if you have any allergies or other illnesses before starting therapy. If you're pregnant, you should only use alglucerase when clearly needed. Lastly, consult your doctor before breastfeeding while under alglucerase treatment.

The alglucerase solution should never be shaken and each bottle should be examined carefully for any discoloration or particulate matter before being used. Any bottles suffering from discoloration or exhibiting particulate matter should be discarded. What's more, you must not use this medication once it has already passed its expiration date.

Studies have shown that about 13% of patients have developed the IgG antibody after one year of alglucerase therapy. This phenomenon usually occurs within six months of treatment; patients who don't develop the IgG antibody within this period will rarely develop it after a year of treatment.

About a quarter of the studied patients with IgG antibodies underwent hypersensitivity symptoms. Simply put, those who've developed antibodies from alglucerase therapy have a higher risk of also developing an allergic reaction.

• Molecular formula of alglucerase is C2532H3854N672O711S16
• Chemical IUPAC Name is Human Beta-glucocerebrosidase
• Molecular weight is 55597.4 g/mol

Brand name(s): Ceredase, Imiglucerase

  Your Alglucerase review